AVN 63.71 Increased By ▲ 0.02 (0.03%)
BOP 8.77 Decreased By ▼ -0.01 (-0.11%)
CHCC 134.55 Increased By ▲ 0.05 (0.04%)
DCL 10.01 Decreased By ▼ -0.04 (-0.4%)
DGKC 108.01 Increased By ▲ 0.01 (0.01%)
EFERT 64.27 Decreased By ▼ -0.18 (-0.28%)
EPCL 41.21 Decreased By ▼ -0.09 (-0.22%)
FCCL 21.00 No Change ▼ 0.00 (0%)
FFL 15.10 Increased By ▲ 0.05 (0.33%)
HASCOL 15.05 Decreased By ▼ -0.03 (-0.2%)
HBL 130.50 Decreased By ▼ -0.60 (-0.46%)
HUBC 81.75 Increased By ▲ 0.13 (0.16%)
HUMNL 7.35 Decreased By ▼ -0.05 (-0.68%)
JSCL 24.29 No Change ▼ 0.00 (0%)
KAPCO 28.49 Increased By ▲ 0.14 (0.49%)
KEL 3.70 Decreased By ▼ -0.01 (-0.27%)
LOTCHEM 11.72 Decreased By ▼ -0.03 (-0.26%)
MLCF 41.98 Increased By ▲ 0.13 (0.31%)
OGDC 93.20 Decreased By ▼ -0.13 (-0.14%)
PAEL 32.90 Decreased By ▼ -0.02 (-0.06%)
PIBTL 12.76 Decreased By ▼ -0.10 (-0.78%)
PIOC 95.00 No Change ▼ 0.00 (0%)
POWER 9.75 Decreased By ▼ -0.02 (-0.2%)
PPL 83.50 Decreased By ▼ -0.10 (-0.12%)
PSO 200.02 Increased By ▲ 0.02 (0.01%)
SNGP 56.52 Decreased By ▼ -0.08 (-0.14%)
STPL 13.15 No Change ▼ 0.00 (0%)
TRG 46.90 Increased By ▲ 0.30 (0.64%)
UNITY 23.05 Increased By ▲ 0.05 (0.22%)
WTL 1.04 Decreased By ▼ -0.01 (-0.95%)
BR100 4,133 Decreased By ▼ -155.2 (-3.62%)
BR30 21,019 Decreased By ▼ -858.48 (-3.92%)
KSE100 39,888 Decreased By ▼ -1298.86 (-3.15%)
KSE30 16,750 Decreased By ▼ -546.72 (-3.16%)
COVID-19 TOTAL DAILY
World

Moderna prices COVID-19 vaccine at $32-$37 per dose for smaller volume deals

  • As the race to develop COVID-19 vaccines reach a decisive stage, pricing has come under increasing scrutiny
05 Aug 2020

Moderna Inc said on Wednesday smaller volume agreements for its experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc's vaccine candidate.

As the race to develop COVID-19 vaccines reach a decisive stage, with several candidates being tested in pivotal late-stage studies, pricing has come under increasing scrutiny.

"We will be responsible on price well below (its) value during the pandemic," Chief Executive Officer Stéphane Bancel said on a conference call, adding that larger volume agreements for its vaccine will be priced lower.

Last month, the U.S. government struck a deal for an experiment vaccine being developed by Pfizer and partner BioNTech SE that secures enough vaccine to inoculate 50 million Americans for about $40 a person. Moderna's two-dose vaccine regimen would cost between $64 and $74 per person.

Moderna, which has no drugs on the market, has received nearly $1 billion from the U.S. government under a plan to speed up vaccine development. It has not struck a supply agreement with the United States.